| Target Molecule | Sincalide (CCK-8, sulfated) |
| Synonyms | CCK-8 (sulfated), Cholecystokinin octapeptide, Kinevac, SQ-19844 |
| CAS Number | 25126-32-3 (sulfated); 25126-31-2 (unsulfated CCK-8) |
| Sequence (3-Letter) | H-Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH₂ |
| Sequence (1-Letter) | D-Y(SO3H)-MGWMDF-NH₂ |
| Molecular Formula | C₄₉H₆₂N₁₀O₁₆S₃ |
| Molecular Weight | 1143.3 |
| Service Category | Custom Peptide Synthesis / CDMO Manufacturing |
| Synthesis Purity | Customizable (e.g., ≥95%, ≥98% via HPLC) |
| Appearance | White to off-white lyophilized powder |
| Counter Ion | Ammonium, acetate, or custom salt options |
| Synthesis Technology | Solid-Phase Peptide Synthesis (SPPS) and Acid-Labile Sulfation Chemistry |
| Modification Options | Tyrosine O-sulfation, C-terminal amidation, stable isotope labeling (13C, 15N), unsulfated CCK-8 controls |
| Available Scale | Milligram (R&D) to Kilogram (Commercial CDMO) |
| Analytical Data | Comprehensive COA, HPLC, MS, and intact sulfation confirmation provided per batch |
| Usage | Raw material synthesized strictly for laboratory research, analytical development, and industrial formulation. Not a finished medicine. |
Sincalide (CAS 25126-32-3) is an 8-residue peptide amide carrying a critical O-sulfated tyrosine residue at position 2 (Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2). We target this sequence to supply high-purity reference materials, analytical calibration markers, and raw materials for cholecystokinin (CCK) receptor pharmacology.
Tyrosine O-sulfate is highly sensitive to acid hydrolysis during standard resin cleavage. Our peptide synthesis platform utilizes specialized mild cleavage protocols and scavenger cocktails combined with low-temperature processing, preventing desulfation while suppressing oxidation of the Met3, Met6, and Trp5 residues.
Yes. We provide extensive peptide modification services for CCK-related sequences. Capabilities include the synthesis of unsulfated CCK-8 (CAS 25126-31-2) as an analytical comparator, site-specific stable isotope labeling (13C, 15N) for LC-MS/MS, and the preparation of defined methionine sulfoxide degradation standards.
Our manufacturing infrastructure scales production from milligram-level analytical batches to multigram and kilogram commercial quantities. We utilize customized, low-acid preparative HPLC purification and controlled counter-ion exchange (such as ammonium or acetate conversion) to ensure strict batch-to-batch consistency without desulfation.
We operate as an integrated technical partner providing complete peptide CDMO solutions. Our team manages sequence optimization, intact sulfation verification, impurity profiling, analytical method validation, and regulatory documentation to accelerate complex preclinical and commercial pipelines.
Sincalide (CAS 25126-32-3), also known as sulfated CCK-8 or Kinevac, is an 8-amino-acid peptide amide defined by the sequence Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2. Functioning as a potent endogenous agonist at cholecystokinin (CCK) receptors, its bioactivity requires the preservation of its acid-labile tyrosine O-sulfate group. Synpeptide delivers comprehensive custom synthesis solutions for this target molecule, showcasing our technical capabilities in labile post-translational modifications, impurity suppression, and CDMO manufacturing.
Synthesizing Sincalide presents severe chemical hurdles due to the extreme acid-lability of the tyrosine sulfate ester during solid-phase peptide synthesis (SPPS) cleavage. Our custom peptide synthesis platform resolves these hurdles using optimized SPPS protocols and specialized mild cleavage regimes. By employing targeted scavengers and low-temperature cleavage protocols, we suppress desulfation and prevent oxidation at the Met and Trp positions, delivering raw materials with rigorous purity specifications (typically ≥95% or ≥98% via HPLC).
Accurate pharmacological profiling and method validation require distinct analytical controls. Through our peptide modification services, we synthesize unsulfated CCK-8 as an essential comparator standard. We also incorporate heavy stable isotopes (13C, 15N) for quantitative mass spectrometry, attach fluorescent labels for receptor localization assays, and synthesize methionine sulfoxide variants as stability-indicating reference standards.
Transitioning an acid-labile sulfated peptide from analytical scale to commercial volume demands specialized downstream process engineering. Acidic chromatographic conditions can trigger desulfation during purification and lyophilization. We execute large-scale peptide synthesis for Sincalide utilizing pH-controlled preparative HPLC and gentle lyophilization cycles. Our infrastructure accommodates requirements from milligram research batches to kilogram commercial lots, ensuring uniform counter-ion exchange (providing ammonium or acetate salt forms) across all production volumes.
We deliver comprehensive technical support as a fully established peptide CDMO. Our development specialists assist pharmaceutical partners with analytical method validation, exact mass verification of the intact sulfate ester, and long-term stability assessments. Every batch is released with complete documentation—including COA, HPLC purity traces, and high-resolution MS data—ensuring regulatory alignment for downstream therapeutic programs.
